Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 okt 2010 - 16:35
Statutaire naam
Crucell N.V.
Titel
Crucell Puts Temporary Hold on Shipments of Quinvaxem and Hepavax-Gene
Bericht
PRESS RELEASE
Crucell Puts Temporary Hold on Shipments of
Quinvaxem® and Hepavax-Gene®
Leiden, the Netherlands (October 28, 2010) – Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has put a temporary hold on all shipments of its fully liquid pentavalent vaccine Quinvaxem® and its hepatitis B vaccine Hepavax-Gene® as the sterile operation of its Shingal facility in Korea may have been compromised during recent operations. The Shingal facility was already scheduled to be vacated next year. The operations in our new Incheon facility are not affected.
Currently the situation is being investigated. As a precautionary measure, Crucell has imposed a hold on all material currently held on stock. Crucell expects to resume shipping before the end of November when results of the investigation are expected to be available.
Datum laatste update: 29 december 2025